Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial
3Citations signalées, ce qui n’est pas une note de qualité
39Institutions déclarées
6Pays d’affiliation déclarés
Rattachement africain : ru, il, us, by, cz, in. Niveau de preuve : code pays fourni par la source.
Résumé indisponible. Les résultats de l’étude ne doivent pas être déduits de son seul titre.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial
- Date Crossref
- 01/09/2025
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Les institutions déclarées
National Medical Research Center of CardiologyState Budget Institution of Health St. Petersburg Clinical Research Center Specialized Types of Medical CareHadassah Medical CenterMoscow City Oncology Hospital №62State Healthcare Institution "Regional Clinical Oncological Dispensary"Budgetary Health Care Institution of the Omsk Region "Clinical Oncology Center"TRC Companies (United States)9th City Clinical HospitalCity Clinical HospitalSteadman ClinicNational Research Mordovia State UniversityVolgograd Regional Clinical Oncology CenterRepublican Clinical Hospital of the Ministry of Health of the Republic of TatarstanBrest State Technical UniversitySt Petersburg UniversityKostroma Research Institute of AgricultureClinical Hospital No. 8Institute of Oncology NN PetrovNizhny Novgorod Regional Clinical Oncology CenterAltai Scientific Research Institute of Machine Building TechnologyNovokuznetsk State Institute of Advanced Medical EducationLeningrad Regional Cancer CenterMedical Technologies (Czechia)All India Institute of Medical SciencesSaint-Petersburg Institute of HistoryVitebsk State University named after P.M. MasherovVitebsk State Academy of Veterinary MedicineVitebsk State Medical UniversityGomel Engineering InstituteChelyabinsk State UniversityGovernment Ayurved College, NandedMedical Radiological Research CenterSechenov UniversityAxis Multispecialty HospitalOncological Dispensary No. 2Arkhangel'skiy Klinicheskiy Onkologicheskiy DispanserSt. Petersburg State Medical Academy "City Hospital No. 26"Chelyabinsk Regional Clinical Oncology CenterBIOCAD (Russia)
Une affiliation ne permet pas de déduire la nationalité d’un auteur.
Les sujets associés
Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and ManagementImmunotherapy and Immune Responses